Watson biological "23 valent pneumococcal polysaccharide vaccine" completed clinical trial

Watson bio announced on March 4 that the company and its wholly-owned subsidiary, Yuxi Watson bio, have jointly applied for the registration of the 23 price vaccine, and have completed the clinical trial Recently, the report of clinical trial of 23 price pneumococcal polysaccharide vaccine issued by the clinical research institute was obtained The report clearly showed that: the clinical trial evaluation results of the trial vaccine reached the preset goal of the trial The 23 price vaccine developed by the company is the ninth category of biological products for prevention The vaccine can be used to prevent pneumonia, meningitis, septicemia and other diseases caused by various serotypes of pneumococcus It is understood that in 2012, about 9.43 million doses of the same kind of products sold on the domestic market were approved by the China National Inspection Institute, which were respectively produced by Sanofi Pasteur, mosadong and Chengdu Institute of biological products The company said it would then apply to the State Food and Drug Administration for approval of 23 price vaccine production as soon as possible in accordance with relevant regulations This clinical trial report of the product will not affect the company's recent performance After rising 7.78% in afternoon trading yesterday, Watson bio's share price fell to close at 52.50 yuan, up 1.06% Xu Keren, Secretary of the board of directors of Watson biology, told reporters that the biggest vaccine in the company's research should be the 13 valent pneumococcal polysaccharide combined vaccine, which has entered the review stage after the information was supplemented at the end of last year 23 price vaccine is also a large-scale variety in the market At present, Chengdu Institute of biological products is the only manufacturer among domestic enterprises The market scale formed now is larger than that of MSD, and the sales situation is also very good The Secretary said that the next stage will start the industrialization of 23 price vaccines Different from other enterprises, vaccine manufacturers need to pass the on-site inspection of clinical approval documents and issue production approval documents before GMP certification However, the current national approval situation may be to pass the on-site verification of three batches of products of the company and conduct GMP verification together, so the progress may be accelerated According to the procedure, in general, 23 price vaccines can be industrialized by the end of 2015